Skip to main navigation
Skip to search
Skip to main content
Icahn School of Medicine at Mount Sinai Home
Help & FAQ
Link opens in a new tab
Search content at Icahn School of Medicine at Mount Sinai
Home
Profiles
Research units
Publications & Research Outputs
Press/Media
Clinical Genetic Testing for APOL1: Are we There Yet?
Bessie A. Young
, Stephanie Malia Fullerton
, James G. Wilson
, Kerri Cavanaugh
, Erika Blacksher
, Clarence Spigner
, Jonathan Himmelfarb
, Wylie Burke
Research output
:
Contribution to journal
›
Review article
›
peer-review
31
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Clinical Genetic Testing for APOL1: Are we There Yet?'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Apolipoprotein L1 (APOL1)
100%
Clinical Genetic Testing
100%
End-stage Renal Disease
75%
African American
25%
Young Age
12%
Comorbid Conditions
12%
Kidney Disease Progression
12%
High Risk
12%
Clinical Care
12%
Population Screening
12%
Counseling
12%
Environmental Exposure
12%
Informed Consent
12%
Kidney Transplant
12%
Risk Variant
12%
European American
12%
Non-diabetic
12%
High-risk HPV
12%
Living Donor
12%
Community Members
12%
Injury Mechanism
12%
Medicine and Dentistry
Genetic Screening
100%
Clinical Genetics
100%
Apolipoprotein L1
100%
End Stage Renal Disease
75%
Chronic Kidney Disease
12%
Counseling
12%
Environmental Exposure
12%
Kidney Graft
12%
Informed Consent
12%
Mass Screening
12%
Living Donors
12%
Psychology
Kidney Disease
100%
Clinical Implication
100%
Informed Consent
100%
Immunology and Microbiology
Genetic Screening
100%
Apolipoprotein
100%
Mass Screening
12%
Biochemistry, Genetics and Molecular Biology
Genetic Screening
100%
Apolipoprotein L1
100%
Mass Screening
12%
Neuroscience
Apolipoprotein L1
100%